These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35467793)

  • 1. Healthcare expenditure of intravitreal anti-vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema.
    Hertzberg SN; Moe MC; Jørstad ØK; Petrovski BÉ; Burger E; Petrovski G
    Acta Ophthalmol; 2022 Dec; 100(8):e1630-e1640. PubMed ID: 35467793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
    Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
    Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
    JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study).
    Gascon P; Borget I; Comet A; Carton L; Matonti F; Dupont-Benjamin L
    Eur J Ophthalmol; 2022 May; 32(3):1702-1709. PubMed ID: 34284605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
    Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
    BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Dexamethasone in Diabetic Macular Oedema: A Way of Enhancing the Response to Anti-VEGF in Non- or Poor Responders?
    Touhami S; Dupas B; Bertaud S; Tadayoni R; Couturier A
    Ophthalmologica; 2022; 245(4):350-357. PubMed ID: 34587614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy.
    Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A
    Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results.
    Patel NA; Al-Khersan H; Yannuzzi NA; Lin J; Smiddy WE
    Ophthalmol Retina; 2023 May; 7(5):413-419. PubMed ID: 36423893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical Lessons from Protocol T for the Management of Diabetic Macular Edema.
    Mukkamala L; Bhagat N; Zarbin M
    Dev Ophthalmol; 2017; 60():109-124. PubMed ID: 28427070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study.
    Comet A; Gascon P; Ramtohul P; Donnadieu B; Denis D; Matonti F
    Eur J Ophthalmol; 2021 Mar; 31(2):754-758. PubMed ID: 32507032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?
    Foglia E; Ferrario L; Bandello F; Ferri C; Figini I; Franzin M; Gambaro G; Introini U; Medaglia M; Staurenghi G; Tadini P; Fomiatti A; Croce D
    Acta Ophthalmol; 2018 Jun; 96(4):e468-e474. PubMed ID: 29240298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial.
    Mehta H; Fraser-Bell S; Nguyen V; Lim LL; Gillies MC
    Ophthalmol Retina; 2018 Mar; 2(3):231-234. PubMed ID: 31047591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.